{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.1","value":"17.8"},{"comment":"Values are not available. Drug clearance was not assessed in the Sirolimus-Active Metabolite arm.","groupId":"OG001","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS.","dispersionType":"Standard Deviation","groups":[{"description":"Clearance was calculated using a single compartment model.","id":"OG000","title":"Temsirolimus- Parent Drug"},{"id":"OG001","title":"Sirolimus- Active Metabolite"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Prior to the initial dose on day 1, then 2, 6, and 24 hours post dose; prior to first dose of Cycle 2, then at 1, 2, 6, 24, 96, and 120 hours post dose in patients treated at the recommended phase 2 dose, Dose Level 4.","title":"Drug Clearance","type":"SECONDARY","unitOfMeasure":"L/hr/m2"}